The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences-Reference-Cited by-同舟云学术

The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences

Published:2022-04 Issue: Volume:172 Page:103602
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Fogli Stefano,Tabbò Fabrizio^ORCID,Capuano Annalisa,Del Re Marzia,Passiglia Francesco,Cucchiara Federico,Scavone Cristina,Gori Veronica,Novello Silvia^ORCID,Schmidinger Manuela,Danesi Romano^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference148 articles.

1. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis;Awad;Lung Cancer.,2019

2. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer;Bahcall;Cancer Discov.,2016

3. Grapefruit juice-drug interactions;Bailey;Br J Clin Pharmacol.,1998

4. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation;Baltschukat;Clin Cancer Res.,2019

5. Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts;Bang;Cancer Sci.,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leveraging class-balancing techniques for predicting c-MET Inhibitors: Descriptor Calculation, Selection, and QSAR Model Optimization using Machine Learning;2024-09-11

2. Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer;Nucleosides, Nucleotides & Nucleic Acids;2024-02-29

3. Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors;Frontiers in Chemistry;2022-11-17

4. A computer-aided drug design approach to explore novel type II inhibitors of c-Met receptor tyrosine kinase for cancer therapy: QSAR, molecular docking, ADMET and molecular dynamics simulations;Journal of Biomolecular Structure and Dynamics;2022-09-19

5. Application of C-MET Inhibitors in the Treatment of Non-small Cell Lung Cancer;Highlights in Science, Engineering and Technology;2022-08-17